RLYP
Relypsa, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Aug. 30, 4:21 PM
    • A Phase 4 study, TOURMALINE, assessing Relypsa's (NASDAQ:RLYP) Veltassa (patiromer) for oral suspension, taken with or without food, for the treatment of hyperkalemia (excess blood potassium) met its primary endpoint.
    • Results showed no statistically significant difference in the proportion of patients achieving serum potassium levels within the target range (3.8 - 5.0 mEq/L) by Week 3 or 4 between those taking Veltassa with food or without. Adverse events were consistent with earlier trials.
    • The data will be submitted for presentation at a future medical conference and will be shared with the FDA.
    • Veltassa is a potassium binder approved in the U.S. for the treatment of hyperkalemia in October 2015.
    | Tue, Aug. 30, 4:21 PM | 6 Comments
  • Fri, Aug. 26, 7:26 AM
    • Bayer AG (OTCPK:BAYRY) upgraded to Buy from Neutral by Citigroup.
    • Allscripts (NASDAQ:MDRX) upgraded to Outperform from Market Perform by Leerink Swann. Price target raised to $17 (32% upside) from $16.
    • Healthways (NASDAQ:HWAY) upgraded to Equal Weight from Underweight by Barclays. Price target raised to $27 (10% upside) from $12.
    • Cardiovascular Systems (NASDAQ:CSII) upgraded to Outperform from Market Perform by Leerink Swann. Price target is $30 (26% upside).
    • Allergan plc (NYSE:AGN) upgraded to Buy from Neutral by Mizuho Securities. Price target raised to $318 (35% upside) from $248.
    • Healthways (HWay) downgraded to Sell from Neutral by UBS. Price target raised to $22.50 (8% downside risk) from $19.
    • ResMed (NYSE:RMD) downgraded to Underperform from Hold by Jefferies. Price target lowered to $58 (15% downside risk) from $60.
    • Relypsa (NASDAQ:RLYP) downgraded to Hold from Buy by Stifel Nicolaus. Price target is $32 (0% upside).
    • Portola Pharmaceuticals (NASDAQ:PTLA) downgraded to Neutral from Buy by Citigroup. Price target lowered to $24 (21% upside) from $40.
    • Juniper Pharmaceuticals (NASDAQ:JNP) downgraded to Neutral from Buy by H.C. Wainwright. Price target is $6.75 (17% upside).
    | Fri, Aug. 26, 7:26 AM | 1 Comment
  • Fri, Jul. 22, 8:40 AM
    • Johnson & Johnson (NYSE:JNJ) upgraded to Buy from Hold by Argus Research. Price target raised to $145 (16% upside) from $130.
    • Humana (NYSE:HUM) upgraded to Buy from Hold by Jefferies. Price target raised to $210 (22% upside) from $199.
    • Teva Pharmaceutical Industries (NYSE:TEVA) upgraded to Buy from Hold by HSBC. Price target raised to $65 (19% upside) from $61.
    • Relypsa (NASDAQ:RLYP) downgraded to Neutral from Buy by Citigroup. Price target raised to $32 (0% upside) from $25.
    • Evoke Pharma (NASDAQ:EVOK) downgraded to Hold from Buy by Noble Financial. Downgraded to Hold from Buy by Brean Capital. Downgraded to Neutral from Buy by Rodman & Renshaw.
    • Merck (NYSE:MRK) downgraded to Market Perform from Outperform with a $62 (5% upside) price target by BMO Capital.
    • St. Jude Medial (NYSE:STJ) downgraded to Neutral from Outperform by Wedbush. Price target raised to $84 (3% upside) from $70.
    • Teva Pharmaceutical Industries (TEVA) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $60 (10% upside) from $70.
    | Fri, Jul. 22, 8:40 AM | 3 Comments
  • Thu, Jul. 21, 12:47 PM
    | Thu, Jul. 21, 12:47 PM
  • Thu, Jul. 21, 11:01 AM
    | Thu, Jul. 21, 11:01 AM | 4 Comments
  • Thu, Jul. 21, 9:15 AM
    | Thu, Jul. 21, 9:15 AM | 1 Comment
  • Thu, Jul. 21, 3:11 AM
    • Galenica (OTC:GNHAY) has agreed to buy Relypsa (NASDAQ:RLYP) for $32 per share in cash, or about $1.53B, representing a 59% premium to Wednesday's close.
    • The acquisition gives the Swiss company's Vifor Pharma unit a U.S. commercial network and global rights to Relypsa's drug Veltassa, which was the first American medicine in 50 years to be approved for hyperkalemia.
    • After the transaction, Galenica plans to split into two separate listed companies.
    • RLYP +56.7% premarket
    | Thu, Jul. 21, 3:11 AM | 63 Comments
  • Mon, Jul. 11, 4:50 PM
    • Relypsa (NASDAQ:RLYP) is up 3% after hours on increased volume in response to the release of the June total of new patients who started Veltassa (patiromer) with a free starter supply. The number for last month was 1,531, up 10.5% from May and up almost 26% from April.
    • Outpatient prescriptions covered and filled were 1,723 for June, up up 40% since May and up almost 86% since April. Hospital/institution units sold rebounded from the dip in May to 392, up over 41% sequentially.
    | Mon, Jul. 11, 4:50 PM | 16 Comments
  • Wed, Jun. 15, 4:19 PM
    • In a regulatory filing, Relypsa (NASDAQ:RLYP) reports that retail prescriptions for hyperkalemia drug Veltassa (patiromer) in May were 1,230, up 32.5% from April. New patients who started with a free starter supply totaled 1,385 (+13.9%). Units sold in the hospital/institution setting, however, were down 3.8% (277 in May versus 288 in April).
    • The company says the numbers are estimates as they have not been verified by a third party.
    • Investors are looking for a healthy ramp considering the company's window of opportunity since competitor AstraZeneca (NYSE:AZN) received a Complete Response Letter (CRL) from the FDA last month regarding its NDA for ZS-9.
    • Previously: FDA rejects AstraZeneca's ZS-9 NDA; competitor Relypsa up 29% premarket (May 27)
    • Update: Shares are now up 6% on turnover of ~100K.
    | Wed, Jun. 15, 4:19 PM | 74 Comments
  • Fri, Jun. 10, 7:28 AM
    • Sarepta Therapeutics (NASDAQ:SRPT) upgraded to Outperform from Neutral by Wedbush. Price target raised to $36 (71% upside) from $14.
    • EnteroMedics (NASDAQ:ETRM) downgraded to Neutral from Buy by Roth Capital Partners. Price target is $0.50 (11% upside).
    • Relypsa (NASDAQ:RLYP) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target maintained at $9 (52% downside risk).
    • Mirati Therapeutics (NASDAQ:MRTX) downgraded to Hold from Buy by Jefferies. Price target lowered to $17 (77% upside) from $27.
    • AbbVie (NYSE:ABBV) downgraded to Market Perform from Outperform by Cowen & Company. Price target lowered to $70 (15% upside) from $77. Downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $65 (7% upside) from $73.
    • WebMD (NASDAQ:WBMD) downgraded to Market Perform from Outperform by William Blair.
    | Fri, Jun. 10, 7:28 AM | 11 Comments
  • Fri, May 27, 4:56 PM
    • Globus Medical (NYSE:GMED) initiated with Equal Weight Rating and $26 (8% upside) price target by Barclays.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating $18 (133% upside) price target by SunTrust Robinson Humphrey.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Outperform rating and $13 (35% upside) price target by Raymond James.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Sell rating and $18 (43% downside risk) price target by Chardan Capital.
    • Viking Therapeutics (NASDAQ:VKTX) initiated with Buy rating with a $5 (285% upside) price target by Maxim Group.
    • Fibrocell Science (NASDAQ:FCSC) resumed with Buy rating and $7 (229% upside) price target by Roth Capital Partners.
    • Asterias Biotherapeutics (NYSEMKT:AST) initiated with Buy rating and $5.50 (61% upside) price target by Chardan Capital.
    • Quorum Health (NYSE:QHC) initiated with Market Perform rating and $14 (6% upside) price target by Avondale Partners.
    • Radius Health (NASDAQ:RDUS) initiated with Buy rating and $55 (57% upside) price target by H.C. Wainwright.
    • Johnson & Johnson (NYSE:JNJ) initiated with Sell rating and $94 (17% downside risk) price target by Standpoint Research.
    • NuVasive (NASDAQ:NUVA) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $63 (15% upside) from $58.
    • Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Buy from Hold with a $125 (2% upside) price target by Argus Research.
    • Relypsa (NASDAQ:RLYP) upgraded to Equal Weight from Underweight with a $9 (50% downside risk) price target by Morgan Stanley. To be adjusted after ZS-9 rejection.
    • Ionis Pharmaceuticals (NASDAQ:IONS) downgraded to Market Perform from Outperform by BMO Capital Markets. Price target lowered to $26 (18% upside) from $55.
    • Patterson Companies (NASDAQ:PDCO) downgraded to Hold from Buy by Evercore ISI. Price target lowered to $48.50 (0% upside) from $49.50.
    • United Therapeutics (NASDAQ:UTHR) downgraded to Sell from Hold with a $114 (3% downside risk) price target by Argus Research.
    • Boston Scientific (NYSE:BSX) downgraded to Neutral from Buy with a $24.20 (7% upside) price target by BTIG Research.
    • Neovasc (NASDAQ:NVCN) downgraded to Neutral from Buy by Ladenburg Thalmann. Price target removed.
    | Fri, May 27, 4:56 PM | 17 Comments
  • Fri, May 27, 11:00 AM
    | Fri, May 27, 11:00 AM
  • Fri, May 27, 9:12 AM
    | Fri, May 27, 9:12 AM
  • Fri, May 27, 7:25 AM
    • In a shot to the corporate solar plexus, AstraZeneca (NYSE:AZN) receives a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) seeking approval of hyperkalemia drug ZS-9 (sodium zirconium cyclosilicate).  In a statement, it said the CRL refers to observations from a pre-approval on-site manufacturing inspection. The agency also cited the receipt of recently-submitted data which it has yet to review. The company is reviewing the CRL to determine appropriate action.
    • AstraZeneca acquired the rights to ZS-9 via its $2.7B acquisition of ZS Pharma in December 2015.
    • Competitor Relypsa (NASDAQ:RLYP) is up 29% premarket on robust volume. Its hyperkalemia drug, Veltassa (patiromer) was approved by the FDA in October 2015.
    • AstraZeneca is down 1% premarket on increased volume.
    | Fri, May 27, 7:25 AM | 30 Comments
  • Wed, May 25, 4:38 PM
    • Relypsa (NASDAQ:RLYP) files a supplemental New Drug Application (sNDA) with the FDA seeking a labeling change for hyperkalemia drug Veltassa (patiromer) reducing the current six-hour dose separation requirement from six hours to three. Its filing is based on the results from 12 Phase 1 drug-drug interaction studies which showed no meaningful reduction in absorption for the majority of drugs tested when separated by the shorter time frame.
    • Veltassa's package insert currently has a black box warning specifying a minimum separation of six hours between patiromer and oral medications because of the risk of lower absorption of the oral meds caused by binding to patiromer. The six-hour requirement has created headwinds to the company's commercial launch which commenced in December 2015. In a recent survey, 90% of respondents said the requirement would limit their use of the product.
    • Previously: Relypsa down 7% premarket as some question Veltassa ramp (May 17)
    | Wed, May 25, 4:38 PM | 28 Comments
  • Mon, May 23, 9:16 AM
    | Mon, May 23, 9:16 AM